Tüdőrák: vizsgálatok itt: Németország
182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Where
- Greifswald, Leipzig, Munich, Stuttgart
- Életkor
- 18 év and over
- People
- 480 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06667076 · EU 2025-520730-28-00 - No phaseTaking peopleA Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
- Where
- Aschaffenburg, Bielefeld, Bochum, Bremen, Chemnitz, Cologne, Düsseldorf, Essen, Hamburg, Hanover, Hemer, Konstanz, Landshut, Neuss, Recklinghausen, Solingen, Stolberg, Ulm
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07230691 - 2. fázisTaking peopleStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- Where
- Berlin, Cologne, Essen, Giessen, Halle (saale), Hanover, Heidelberg, Mannheim
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- Genmab
See details and how to joinNCT07288177 · EU 2025-522107-18-00 - 2/3. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Where
- Aachen, Augsburg, Berlin, Bonn, Chemnitz, Duesseldorf, Erlangen, Esslingen am Neckar, Frankfurt am Main, Gauting, Gera, Giessen, Halle (Saale), Hamburg, Hanover, Heidelberg, Immenhausen Hesse, Koblenz, Mainz, Moers, Muenster, Munich, Neuss, Oldenburg, Remscheid, Rostock, St. Juergen Luebeck, Tuebingen, Wuppertal
- Életkor
- 18 év and over
- People
- 1580 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00 - 3. fázisNot yet taking people in NémetországClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Where
- Amberg, Berlin, Cologne, Esslingen am Neckar, Gauting, Ravensburg
- Életkor
- 18 év to 90 év
- People
- 507 worldwide
- Run by
- ImmunityBio, Inc.
See details and how to joinNCT06745908 · EU 2025-521221-32-00 - 3. fázisTaking peopleBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Berlin, Cologne, Esslingen am Neckar, Frankfurt Am Main, Gauting, Grosshansdorf, Heidelberg, Oldenburg, Wuerzburg
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00 - 2/3. fázisTaking peoplePhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Amberg, Augsburg, Bad Homburg, Brunswick, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt am Main, Giessen, Grosshansdorf, Hamburg, Hanover, Hemer, Immenstadt I. Allgäu, Kaiserslautern, Kassel, Kempten (Allgau), Krefeld, Loewenstein, Luebeck, Moenchengladbach, Munich, Neuruppin, Offenbach Am Main, Trier, Ulm
- Életkor
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00 - 1/2. fázisTaking peopleFirst-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Where
- Berlin, Dresden, Frankfurt Am Main, Munich
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Pierre Fabre Medicament
See details and how to joinNCT06043817 · EU 2023-506759-51-00 - No phaseTaking peopleMore Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
- Where
- Erlangen
- Életkor
- 3 év and over
- People
- 180
- Run by
- University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07705178 - 3. fázisTaking peopleA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Bad Berka, Berlin, Dresden, Gauting, Giessen, Hamburg, Heidelberg, Kassel, Mannheim
- Életkor
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00 - 3. fázisTaking peoplePembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Berlin, Dortmund, Essen, Gera, Luebeck, Solingen
- Életkor
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Where
- Bad Berka, Berlin, Bielefeld, Bochum, Cologne, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Hamburg, Hanover, Heidelberg, Hemer, Homburg, Jena, Kassel, Kiel, Krefeld, Magdeburg, Minden, Moers, Munich, Oldenburg in Holstein, Regensburg, Schwerin, Wuerzburg
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00 - 2. fázisNot yet taking people in NémetországDB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Where
- Frankfurt am Main, Giessen
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00 - 3. fázisTaking peoplePhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Where
- Berlin, Bonn, Cologne, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Kempten (Allgau), Kiel, Koblenz, Munich, Nuremberg, Potsdam, Ravensburg
- Életkor
- 18 év and over
- People
- 675 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- Where
- Bad Berka, Bielefeld, Bochum, Chemnitz, Cologne, Esslingen am Neckar, Frankfurt am Main, Gauting, Giessen, Grosshansdorf, Halle, Hamburg, Hanover, Hemer, Homburg, Karlsruhe, Kassel, Kiel, Krefeld, Magdeburg, Minden, Moers, Munich, Oldenburg in Holstein, Regensburg, Schwerin, Velbert, Wuerzburg
- Életkor
- 18 év and over
- People
- 1160 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00 - 3. fázisNot yet taking people in NémetországA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
- Where
- Berlin, Essen, Munich, Oldenburg
- Életkor
- 18 év and over
- People
- 390 worldwide
- Run by
- ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00 - 1/2. fázisNot yet taking people in NémetországA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Where
- Munich, Regensburg, Wuerzburg
- Életkor
- 18 év and over
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01 - 1/2. fázisTaking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Augsburg, Cologne, Frankfurt Am Main, Freiburg im Breisgau, Hemer, Jena, Loewenstein, Oldenburg in Holstein, Wuerzburg
- Életkor
- 18 év and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - 3. fázisTaking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Berlin, Cologne, Esslingen am Neckar, Flensburg, Frankfurt am Main, Gera, Giessen, Halle (Saale), Hannover, Hemer, Herne, Jena, Munich, Oldenburg, Stuttgart, Ulm, Wuerzburg
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - 2. fázisTaking peopleA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Where
- Berlin, Giessen, Immenhausen
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Frankfurt
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 2. fázisTaking peopleTrial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- Where
- Bielefeld, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Heidelberg, Moers, Wuerzburg
- Életkor
- 18 év and over
- People
- 131 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07246863 · EU 2024-516794-70-00 - 3. fázisNot yet taking people in NémetországAddition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
- Where
- Berlin, Bremen, Dortmund, Dresden, Esslingen am Neckar, Frankfurt Am Main, Hemer, Homburg, Landshut, Munich, Regensburg, Saarbrücken, Wermelskirchen, Westerstede, Witten, Wuppertal
- Életkor
- 18 év and over
- People
- 230
- Run by
- AIO-Studien-gGmbH
See details and how to joinNCT07715396 · EU 2026-525497-18-00 - 2. fázisFut, nem toborozStudy to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
- Where
- Berlin, Bielefeld, Cologne, Dresden, Essen, Flensburg, Frankfurt Am Main, Goettingen, Hemer, Mainz, Minden, Moers, Munich, Stuttgart
- Életkor
- 18 év and over
- People
- 57
- Run by
- AIO-Studien-gGmbH
See details and how to joinNCT07803848 · EU 2025-522437-65-00 - 3. fázisTaking peopleA phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
- Where
- Aachen, Berlin, Bonn, Essen, Gauting, Giessen, Grosshansdorf, Halle (saale), Heidelberg, Kassel, Munich, Stuttgart
- Életkor
- 18 év and over
- People
- 340 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to join2023-509340-10-00